This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
schema	http://schema.org/
rdfs	http://www.w3.org/2000/01/rdf-schema#
skos	http://www.w3.org/2004/02/skos/core#
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q65355032

rdf:type

wikibase:Item

schema:description

ensayu clínicu clinical trial клінічне випробування klinisch onderzoek

rdfs:label

A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia

skos:prefLabel

A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia

schema:name

A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia

p:P582

wds:Q65355032-8C89B72A-E536-44C2-91F9-F958A3E59581

wdt:P582

2015-09-01T00:00:00Z

p:P31

wds:Q65355032-253CFC48-4888-46CE-90ED-FAFE09192962

wdt:P31

wd:Q30612

p:P580

wds:Q65355032-C8650965-07C9-4408-8EF4-106BD64C68D2

wdt:P580

2014-08-01T00:00:00Z

p:P6153

wds:Q65355032-1097B0C3-4887-4E06-ABD3-F2694325230E wds:Q65355032-191464CD-E299-40E0-A257-49A5BDE486E4 wds:Q65355032-95ACB79F-E3A5-465F-81C9-D72E0B09431A wds:Q65355032-AE8A54EC-E12C-441B-A732-3C94494CDF2D wds:Q65355032-C8F834E4-BD6B-4125-9A55-CF81C2911310 wds:Q65355032-CD13C5BC-20B1-4220-96CF-BB940835BD71 wds:Q65355032-E17CE35A-1773-4FD3-94AF-93324140AAD6 wds:Q65355032-EC898C1C-CD54-46EE-B036-C5C7B33A0BBF wds:Q65355032-30CC033E-0BDF-42BE-81EB-CE758528DA8C wds:Q65355032-30CC08C8-09C0-4204-973C-B9B1CEEAF057 wds:Q65355032-3809D5BF-0232-4D07-A75D-0FE2441E2952

wdt:P6153

wd:Q12616442 wd:Q39988 wd:Q30253976 wd:Q39997 wd:Q489488 wd:Q496536 wd:Q16188802 wd:Q16095606 wd:Q4403855 wd:Q491082 wd:Q626783

p:P2899

wds:Q65355032-0F479E3B-9182-4734-AC06-E5F4325CCD1E

wdt:P2899

20

p:P1050

wds:Q65355032-13C9118D-5FC9-43E7-AECB-611FC2A6ADE6 wds:Q65355032-5626AA6F-E458-43D0-BC3F-B79B4E35210B

wdt:P1050

wd:Q988405 wd:Q41861

p:P1132

wds:Q65355032-19E5D2DE-F5DE-4EF5-AA9C-5A37D4E77821

wdt:P1132

140

p:P4135

wds:Q65355032-DB2F5A0B-A9C6-432C-A2BE-F26287CBD2CF

wdt:P4135

75

p:P8363

wds:Q65355032-0E4874DA-552C-4EBD-8DBE-2C7BA1B26D8C

wdt:P8363

wd:Q78089383

p:P3098

wds:Q65355032-344F1186-D65D-4F44-A572-2DAD3705AFB2

wdt:P3098

NCT02166814

p:P6099

wds:Q65355032-205C395C-58F1-4311-8BF4-A695CF6CA237

wdt:P6099

wd:Q42824827